Scaling for What’s Next in EMEA  

As the advanced therapy medicinal products (ATMP) sector continues to expand across Europe and beyond, the infrastructure supporting these therapies needs to evolve just as quickly. Cryoport Systems is doing exactly that by scaling capabilities, deepening partnerships, and investing in new infrastructure to meet the growing needs of therapy developers.  

In her recent interview with Beyond Biotech, Alison Pritchard, Vice President of Business Development for Cryoport Systems in EMEA, shared how the company is preparing for what’s next in the ATMP space. From a new facility just outside of Paris to expanded service offerings and deeper industry engagement, Cryoport Systems is building a future-ready platform designed to support the full lifecycle of advanced therapies.  

A New Hub in the Heart of Europe 

At the center of Cryoport Systems’ recent expansion is its new Global Supply Chain Center in Louvres, France, strategically located near Charles de Gaulle airport, just outside of Paris. This state-of-the-art facility is designed to serve as a central hub for both European and global distribution, supporting the increasingly complex and temperature-sensitive logistics required by ATMP developers. 

“Paris is a strategic location in the heart of Europe,” Alison said. “It enhances our ability to deliver reliable and scalable supply chain solutions and introduces greater value and efficiency to our clients.”  

The Louvres facility marks a significant milestone in Cryoport Systems’ broader global footprint, which already includes facilities across North America, Asia-Pacific, and Europe. In EMEA alone, Cryoport Systems operates facilities in Stevenage (United Kingdom), Hoofddorp (Netherlands), Villers-le-Bouillet (Belgium), Pont-du-Château (France), and Clermont-Ferrand (France). Together, these sites form a robust and interconnected network that supports therapy developers at every stage, from clinical trials to commercial launch.  

The new Paris-area facility will offer phased capabilities, starting with logistics and shipping system provisioning available now, and expanding into BioServices like GMP-compliant biostorage in subsequent phases. These services are designed to support both clinical and commercial ATMP programs, with additional capabilities such as secondary packaging and additional Qualified Person (QP) oversight planned as the facility scales.  

By consolidating the full, end-to-end supply chain for advanced therapies under one roof, Cryoport Systems is streamlining the therapy journey and reducing the friction that often comes with multi-vendor coordination. More importantly, this expansion is about building capacity for where the market is headed, not just where it stands today.  

“We’re seeing more therapies reach the clinic and a faster pace of approvals globally,” Alison noted. “This puts pressure on infrastructure, and we’re responding by building scalable, localized solutions that can grow with our clients.”  

As the ATMP sector continues to evolve, Cryoport Systems is positioning itself to meet the moment with infrastructure designed for flexibility and global reach.  

Expanded Capabilities for a Growing Market 

Cryoport Systems’ infrastructure expansion is matched by its growing suite of services. From cryopreservation of patient apheresis material to QP release and GMP storage, the company is building a platform that supports therapy developers from early-stage clinical trials through commercialization on a global scale.  

“We’re not only a logistics provider,” Alison emphasized. “We’ve evolved into an end-to-end supply chain solutions provider.”  

One example of this evolution is Cryoport Systems’ IntegriCell^® platform, which standardizes cryopreservation of leukapheresis-derived starting materials. By introducing consistency at the earliest stages of the therapy lifecycle, developers can reduce risk, improve quality, and ultimately, lay the groundwork for scale.  

“With autologous therapies, timing is absolutely critical,” Alison explained. “You’re not just managing logistics. You’re synchronizing with a patient’s clinic appointment, coordinating manufacturing, and ensuring the therapy returns in time for reinfusion.”  

An integrated supply chain platform that brings together key services like cryopreservation, biostorage, and logistics streamlines the entire product lifecycle, laying the groundwork for scale from the earliest stages. 

Engaging with the Ecosystem 

Cryoport Systems is going beyond just building infrastructure and is actively shaping the future of ATMP delivery through industry collaboration. The company is an active participant in regulatory and clinical networks.  

“We’re leaning into collaboration more than ever before,” Alison noted. “It’s about listening carefully to pain points across the ecosystem and designing systems that reflect the complexity of the real world.”  

In a recent conversation, Alison mentioned, Cryoport Systems identified a lack of standardization in the first and last few hundred meters of the delivery chain as a key challenge. By understanding these operational gaps, the company is refining its processes and infrastructure to better support therapy delivery.  

The company also works in partnership with therapy developers, CDMOs, and CROs to co-design logistics strategies that are fit-for-purpose and built for scale.  

“These multiparty relationships become real enablers of efficiency and consistency,” Alison pointed out. “By collaborating closely, we can collectively troubleshoot emerging challenges and refine our supply chain solutions.”  

This collaborative approach helps eliminate traditional friction points (like handoffs between manufacturing and distribution) and ensures that therapies move seamlessly from production to patient.  

Built for Agility, Designed for Scale 

As global dynamics continue to shift, agility is no longer optional. Cryoport Systems is building supply chains that can pivot quickly in response to geopolitical events, regulatory changes, and ever-evolving market demands in as close to real time as possible.  

“Even the most meticulously planned supply chain can be vulnerable to disruption,” Alison said. “You have to build in contingency plans and communication.”  

With continuous condition monitoring, validated infrastructure and shipping systems, and a global network of facilities, Cryoport Systems is helping developers build resilient, patient-centered supply chains that are ready for what’s next. 

In a field where every shipment can represent a life-changing therapy, agility is a clinical imperative. Cryoport Systems is building supply chains that not only respond to disruption but also anticipate it. By combining visibility with validated infrastructure and deep industry collaboration, therapy developers can move beyond reactive logistics toward proactive, patient-centered delivery. Because scaling for what’s next isn’t just about growth. It’s about readiness. It’s about resilience. And it’s about the unwavering commitment to Enabling the Outcome™ for every patient, everywhere.  

You can listen to the full podcast interview with Alison Pritchard here.